BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26275921)

  • 1. Predictive factors for sentinel lymph nodes and non-sentinel lymph nodes metastatic involvement: a database study of 1,041 melanoma patients.
    Kibrité A; Milot H; Douville P; Gagné ÉJ; Labonté S; Friede J; Morin F; Ouellet JF; Claveau J
    Am J Surg; 2016 Jan; 211(1):89-94. PubMed ID: 26275921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
    Wat H; Senthilselvan A; Salopek TG
    J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
    Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?
    Frankel TL; Griffith KA; Lowe L; Wong SL; Bichakjian CK; Chang AE; Cimmino VM; Bradford CR; Rees RS; Johnson TM; Sabel MS
    Ann Surg Oncol; 2008 Sep; 15(9):2403-11. PubMed ID: 18626721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
    Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
    Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
    Fujisawa Y; Otsuka F;
    Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
    Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma.
    Scoggins CR; Bowen AL; Martin RC; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; Hagendoorn L; McMasters KM
    Arch Surg; 2010 Jul; 145(7):622-7. PubMed ID: 20644123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
    Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
    Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
    Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
    Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
    Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
    Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
    Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
    J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
    Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
    Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.
    Sabel MS; Griffith K; Sondak VK; Lowe L; Schwartz JL; Cimmino VM; Chang AE; Rees RS; Bradford CR; Johnson TM
    J Am Coll Surg; 2005 Jul; 201(1):37-47. PubMed ID: 15978442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma.
    Vuylsteke RJ; Borgstein PJ; van Leeuwen PA; Gietema HA; Molenkamp BG; Statius Muller MG; van Diest PJ; van der Sijp JR; Meijer S
    Ann Surg Oncol; 2005 Jun; 12(6):440-8. PubMed ID: 15864481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity of stage III melanoma in the era of sentinel lymph node biopsy.
    Egger ME; Callender GG; McMasters KM; Ross MI; Martin RC; Edwards MJ; Urist MM; Noyes RD; Sussman JJ; Reintgen DS; Stromberg AJ; Scoggins CR
    Ann Surg Oncol; 2013 Mar; 20(3):956-63. PubMed ID: 23064795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.